Accueil   Diary - News   All news ERYTECH submits marketing authorization application

ERYTECH submits marketing authorization application

ERYTECH Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ERY-ASP (Invented Name: GRASPA®) for the treatment of patients with acute lymphoblastic leukemia (ALL).


Read the press release



By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree